

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/10381 A1

(51) International Patent Classification⁷: **C12N 15/12**,
15/63, 1/21, 15/62, C07K 14/47, 16/18, G01N 33/53,
C12Q 1/68

(21) International Application Number: PCT/EP01/08287

(22) International Filing Date: 18 July 2001 (18.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00116452.4 28 July 2000 (28.07.2000) EP

(71) Applicant (for all designated States except US): **MERCK
PATENT GMBH** [DE/DE]; Frankfurter Strasse 250,
64293 Darmstadt (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **HENTSCH, Bernd**
[DE/DE]; Kaupstrasse 48, 64289 Darmstadt (DE).

(74) Common Representative: **MERCK PATENT GMBH**;
Frankfurter Strasse 250, 64293 Darmstadt (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/10381 A1

(54) Title: NOVEL PROTEIN INHIBITOR OF APOPTOSIS PROTEINS

(57) Abstract: IAPL-7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods are utilizing IAPL-7 polypeptides and polynucleotides in diagnostic assays.

Novel protein inhibitor of Apoptosis proteins

Field of the Invention

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides sometimes hereinafter referred to as „novel family member of inhibitor of apoptosis proteins (IAPL-7)“, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

10

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

15

20 Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

25

Summary of the Invention

The present invention relates to IAPL-7, in particular IAPL-7 polypeptides and IAPL-7 polynucleotides, recombinant materials and methods for their production. The DNA sequence of IAPL-7 displays homologies to members of the IAP (Inhibitors of Apoptosis Proteins) gene family.

30

Therefore, it might represent a novel IAP protein family member. The IAPL-7 gene sequence matches to sequences of genomic DNA clones which locate this gene to chromosome 19. Besides its homology to regions of a variety of human IAP proteins, IAPL-7 also displays
5 homology to a rat IAP gene, RIAP-3 (Accession: AB833366).

Such IAPL-7 polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, hyperproliferative diseases, such as cancer, aiming at the facilitation of apoptotic processes in such diseased cells (e.g. cancer cells) hereinafter
10 referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with IAPL-7 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic
15 assays for detecting diseases associated with inappropriate IAPL-7 activity or levels.

Description of the Invention

In a first aspect, the present invention relates to IAPL-7 polypeptides.
20 Such polypeptides include:

- (a) a polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1 and/or SEQ ID NO:3;
- (b) a polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of
25 SEQ ID NO:2 and/or SEQ ID NO:4;
- (c) a polypeptide comprising the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;
- (d) a polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;
- 30 (e) the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4; and

(f) a polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;

(g) fragments and variants of such polypeptides in (a) to (f).

5 Polypeptides of the present invention are believed to be members of the Inhibitor of Apoptosis Protein (IAP) family of polypeptides. They are therefore of interest because they are a widely expressed gene family of apoptotic inhibitors from both phylogenic and physiologic points of view. The diversity of triggers against which the IAPs suppress apoptosis is
10 greater than that observed for any other family of apoptotic inhibitors including the bcl-2 family. The central mechanisms of IAP-mediated apoptotic suppression appear to be through direct caspase and pro-caspase inhibition (primarily caspase 3 and 7).

The second line of evidence for IAP involvement in cancer comes from
15 their emerging role as mediators and regulators of the anti-apoptotic activity of ν -Rel and NF-kappa B transcription factor families. The IAPs have been shown to be induced by NF-kappa B or ν -Rel in multiple cell lines and conversely, HIAP1 and HIAP2 have been shown to activate NF-kappa B possibly forming a positive feed-back loop. Overall a picture
20 consistent with an IAP role in tumour progression rather than tumour initiation is emerging making the IAPs an attractive therapeutic target (see also recent review: Deveraux and Reed in Genes & Development: vol 13, no 3, pp 239-252, 1999).

The human IAP genes prevent cell death across species, implying that
25 they act at a central, highly conserved point in the cell death cascade..

The biological properties of the IAPL-7 are hereinafter referred to as "biological activity of IAPL-7" or "IAPL-7 activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of IAPL-7.

30 Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in

which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

5 Preferred fragments of polypeptides of the present invention include a polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, or a polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO: 2. Preferred fragments are
10 biologically active fragments that mediate the biological activity of IAPL-7, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

15 Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is
20 often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

25 Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods.. Means for preparing such polypeptides are well understood in the art.

30

In a further aspect, the present invention relates to IAPL-7 polynucleotides. Such polynucleotides include:

- (a) a polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3;
- (b) a polynucleotide comprising the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3;
- (c) a polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3;
- (d) the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3;
- (e) a polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;
- (f) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4;
- (g) a polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;
- (h) a polynucleotide encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4;
- (i) a polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3;
- (j) a polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4; and

polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include a polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of SEQ ID NO: 1, or

a polynucleotide comprising an sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the sequence of SEQ ID NO: 1.

5 Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

10 Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

15 In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

- (a) comprises an RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4;
 - (b) is the RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4;
 - (c) comprises an RNA transcript of the DNA sequence of SEQ ID NO:1 and/or SEQ ID NO:3; or
 - (d) is the RNA transcript of the DNA sequence of SEQ ID NO:1 and/or SEQ ID NO:3;
- 25 and RNA polynucleotides that are complementary thereto.

30 The polynucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3 shows homology with IAPs (see Deveraux and Reed for recent review; Genes & Development: vol 13, no 3, pp 239-252, 1999). The polynucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3 is a cDNA sequence that encodes the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4. The

5 polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4 may be identical to the polypeptide encoding sequence of SEQ ID NO:1 and/or SEQ ID NO:3 or it may be a sequence other than SEQ ID NO:1 and/or SEQ ID NO:3, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4. The polypeptide of the SEQ ID NO:2 and/or SEQ ID NO:4 is related to other proteins of the Inhibitor of Apoptosis Proteins (IAPs) family, having homology and/or structural similarity with Inhibitor of Apoptosis Proteins (IAPs).

10 Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one IAPL-7 activity.

15

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of e.g. human testes tumor tissue, (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

25 When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3'

35

sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

5 Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and
10 genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1 and/or SEQ ID NO:3, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30
15 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process
20 comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan.
25 Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about
30 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 and/or SEQ ID NO:3 or a fragment thereof, preferably of at least 15 nucleotides.

35 The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide

does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such

proteins using RNAs derived from the DNA constructs of the present invention.

5 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook *et al. (ibid)*. Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

10 Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

20 A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, *e.g.*, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al., (ibid)*. Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the

35

periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in

comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled IAPL-7 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising IAPL-7 polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

(a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment or an RNA transcript thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4 or a fragment thereof; or

5 (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

10

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, Nature Genetics 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH

15

20

25

30

35

DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>. The gene of the present invention maps to human chromosome 19 .

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridisation techniques to clones arrayed on a grid, such as cDNA microarray hybridisation (Schena *et al*, Science, 270, 467-470, 1995 and Shalon *et al*, Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

The polypeptides of the present invention are expressed e.g. in human testes tumor tissue .

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific"

means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

5 Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C.,
10 Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

15 Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

20 The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

25 Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to
30 protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to
35 induce such an immunological response to produce antibody to protect

said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use as a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a

structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

5 The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist).
10 Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist
15 by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a IAPL-7 activity in the mixture, and comparing the IAPL-7 activity of the mixture to a control mixture
20 which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging
25 methods such as the nanowell method described by Schullek *et al.*, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and IAPL-7 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).
30

Screening techniques

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and IAPL-7 gene. The art of constructing transgenic animals is well established. For example, the IAPL-7 gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically

modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful
5 in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous
10 DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large
15 amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- 20 (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that of SEQ ID NO:2 and/or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may
25 comprise a substantial component.

Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

5 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of
10 its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

15 "Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is
20 mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also
25 includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or
30 metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

35 "Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds,

i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.

5 "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.

10 Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications.

15 Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance,

20 Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646,

25 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

30

35

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of SEQ ID NO:1 and/or SEQ ID NO:3..

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

5 "Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

15 "Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

20 "Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

25 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being

30

35

compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

5 "Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of
10 the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

15 Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the
20 programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the
25 best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the
30 algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4
35 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5

in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

5 Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences
10 are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either
15 individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted,
20 substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following
25 equation:

$$n_a \leq x_a - (x_a \bullet I),$$

in which:

n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in SEQ ID NO:1
30 and/or SEQ ID NO:3 or SEQ ID NO:2 and/or SEQ ID NO:4, respectively,

I is the Identity Index ,

\bullet is the symbol for the multiplication operator, and

in which any non-integer product of x_a and l is rounded down to the nearest integer prior to subtracting it from x_a .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

"Fusion protein" refers to a protein encoded by two, unrelated, fused genes or fragments thereof. Examples have been disclosed in US 5541087, 5726044. In the case of Fc-IAPL-7, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for performing the functional expression of Fc-IAPL-7 or fragments of IAPL-7, to improve pharmacokinetic properties of such a fusion protein when used for therapy and to generate a dimeric IAPL-7. The Fc-IAPL-7 DNA construct comprises in 5' to 3' direction, a secretion cassette, i.e. a signal sequence that triggers export from a mammalian cell, DNA encoding an immunoglobulin Fc region fragment, as a fusion partner, and a DNA encoding IAPL-7 or fragments thereof. In some uses it would be desirable to be able to alter the intrinsic functional properties (complement binding, Fc-Receptor binding) by mutating the functional Fc sides while leaving the rest of the fusion protein untouched or delete the Fc part completely after expression.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Claims

1. A polypeptide selected from one of the groups consisting of:
 - (a) a polypeptide encoded by a polynucleotide comprising thesequence of SEQ ID NO:1 and/or SEQ ID NO:3;
 - 5 (b) a polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;
 - (c) a polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4; and
 - 10 (d) the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4 and (e)fragments and variants of such polypeptides in (a) to (d).

2. The polypeptide as claimed in claim 1 comprising the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4.

- 15 3. The polypeptide as claimed in claim 1 which is the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4.

4. A polynucleotide selected from one of the groups consisting of:
 - (a) a polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3;
 - 20 (b) a polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3;
 - (c) a polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;
 - 25

(d) a polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2 and/or SEQ ID NO:4;

5 (e) a polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;

(f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);

10 or a polynucleotide sequence complementary to said polynucleotide

and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

15 5. A polynucleotide as claimed in claim 4 selected from the group consisting of:

(a) a polynucleotide comprising the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3;

(b) the polynucleotide of SEQ ID NO:1 and/or SEQ ID NO:3;

20 (c) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4; and

(d) a polynucleotide encoding the polypeptide of SEQ ID NO:2 and/or SEQ ID NO:4.

25 6. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.

7. A recombinant host cell comprising the expression vector of claim 6 or a membrane thereof expressing the polypeptide of claim 1.

5 8. A process for producing a polypeptide of claim 1 comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

10 9. A fusion protein consisting of the Immunoglobulin Fc-region and any one polypeptide of claim 1.

10 10. An antibody immunospecific for the polypeptide of any one of claims 1 to 3.

15 11. A method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of claim 1 comprising a method selected from the group consisting of:

(a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

20 (b) measuring the competition of binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

25 (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide;

(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance, an ELISA assay, and

5

(f) producing said compound according to biotechnological or chemical standard techniques.

SEQUENCE LISTING

<110> Merck Patent GmbH

5 <120> Novel inhibitor of apoptosis protein

<130> IAPL-7BHWS

<140>

10 <141>

<160> 4

<170> PatentIn Ver. 2.1

15 <210> 1

<211> 1758

<212> DNA

<213> Homo sapiens

20 <220>

<221> CDS

<222> (286)..(1680)

25 <400> 1

ccttggcggc tccccagagc gcgcgggtgct aatcgtgggt cgtcagcctg ggtggctggg 60

cccggcttag ggcagggttt ggcatttcca atggtagggg gctcggaccg tccctccgcg 120

30 ggaccctccc gttgggacaa ggccgatcgc ctgggcggtt ggagccgcta tcctggcgcg 180

agacggtgga caagtcctat attcaagaga agataacttt gaacagtttc gaaggatcta 240

aaacgtatgt gtctgcagac atcaatgagg atgaagaatt agtag aag aga tta ata 297

35 Lys Arg Leu Ile
1

gat caa aaa cgt ttg ctg gct ttg cag gtg gtg ggc ctg cct ggg cat 345

40 Asp Gln Lys Arg Leu Leu Ala Leu Gln Val Val Gly Leu Pro Gly His
5 10 15 20

cgg cgc gtt gga gga gac gcc ctg ggg ggc ctt agc tgc cct gaa gcg 393

45 Arg Arg Val Gly Gly Asp Ala Leu Gly Gly Leu Ser Cys Pro Glu Ala
25 30 35

gta gac agg tgg caa cgt ggg ggc tca gga gtt gac aaa cac aag aaa 441

Val Asp Arg Trp Gln Arg Gly Gly Ser Gly Val Asp Lys His Lys Lys
40 45 50

50 gca gcg ccg aat tgc agg ttt atc cgc agc ttt tat ttt gaa gac agt 489

Ala Ala Pro Asn Cys Arg Phe Ile Arg Ser Phe Tyr Phe Glu Asp Ser
55 60 65

gcc acg aaa cct gca aat cct ggt gtc cca aat agt caa tac caa gtt 537

55 Ala Thr Lys Pro Ala Asn Pro Gly Val Pro Asn Ser Gln Tyr Gln Val
70 75 80

gaa aac cat ctg gga gag gaa aag cgt tgt gct tta gac agg ccg tct 585

60 Glu Asn His Leu Gly Glu Glu Lys Arg Cys Ala Leu Asp Arg Pro Ser
85 90 95 100

2/6

	gag act cgt gca gac cgg ctt ttg aga gct gga cag gtg gtg gat aga	633
	Glu Thr Arg Ala Asp Arg Leu Leu Arg Ala Gly Gln Val Val Asp Arg	
	105 110 115	
5	tca gac tcc ata cac ccg agg agc ccc gcc atg cat agt gaa gaa gct	681
	Ser Asp Ser Ile His Pro Arg Ser Pro Ala Met His Ser Glu Glu Ala	
	120 125 130	
10	aga tta cag tgc ttt cac aac tgg cca gcc tct gcc cac ttg acc ccg	729
	Arg Leu Gln Ser Phe His Asn Trp Pro Ala Ser Ala His Leu Thr Pro	
	135 140 145	
15	aga gag ctg gcc agt gct ggg ctg tac tac aca ggc act gat gac caa	777
	Arg Glu Leu Ala Ser Ala Gly Leu Tyr Tyr Thr Gly Thr Asp Asp Gln	
	150 155 160	
20	gtg cag tgc ttc tgt tgt ggc gga aaa ctg aaa aac tgg gaa cct ggt	825
	Val Gln Cys Phe Cys Cys Gly Gly Lys Leu Lys Asn Trp Glu Pro Gly	
	165 170 175 180	
25	gat cgt gcc tgg tca gaa cac agg aga cat ttt cct aat tgc ttc ttt	873
	Asp Arg Ala Trp Ser Glu His Arg Arg His Phe Pro Asn Cys Phe Phe	
	185 190 195	
30	att ttg ggc cac aac gtt aat att cga ggt gaa tct gat gtt gcg agt	921
	Ile Leu Gly His Asn Val Asn Ile Arg Gly Glu Ser Asp Val Ala Ser	
	200 205 210	
35	tct gat agg aat ttc tca aat tca aca agt tct cca agg aat cca tcc	969
	Ser Asp Arg Asn Phe Ser Asn Ser Thr Ser Ser Pro Arg Asn Pro Ser	
	215 220 225	
40	atg acg ggt tat gaa gcc cgg ctc att act ttt ggg aca tgg atg tac	1017
	Met Thr Gly Tyr Glu Ala Arg Leu Ile Thr Phe Gly Thr Trp Met Tyr	
	230 235 240	
45	tcc gtt aac aaa gag cag ctt gca aga gct gga ttt tat gct ata ggt	1065
	Ser Val Asn Lys Glu Gln Leu Ala Arg Ala Gly Phe Tyr Ala Ile Gly	
	245 250 255 260	
50	caa gag gat aaa gta cag tgc ttt cac tgt gga gga ggg cta gcc aac	1113
	Gln Glu Asp Lys Val Gln Cys Phe His Cys Gly Gly Gly Leu Ala Asn	
	265 270 275	
55	tgg aag ccc aag gaa gat cct tgg gaa cag cat gct aaa tgg tat cca	1161
	Trp Lys Pro Lys Glu Asp Pro Trp Glu Gln His Ala Lys Trp Tyr Pro	
	280 285 290	
60	ggt tgc aaa tat ctg cta gaa gag aag gga cat gaa tat ata aac aac	1209
	Gly Cys Lys Tyr Leu Leu Glu Glu Lys Gly His Glu Tyr Ile Asn Asn	
	295 300 305	
65	att cat tta acc cgt tca ctt gag gga gct ctg gta caa act acc aag	1257
	Ile His Leu Thr Arg Ser Leu Glu Gly Ala Leu Val Gln Thr Thr Lys	
	310 315 320	
70	aaa aca cca tca cta act aaa aga atc agt gat acc atc ttc cct aat	1305
	Lys Thr Pro Ser Leu Thr Lys Arg Ile Ser Asp Thr Ile Phe Pro Asn	
	325 330 335 340	
75	cct atg cta caa gaa gct ata cga atg gga ttt gat ttc aag gac gtt	1353

Pro Met Leu Gln Glu Ala Ile Arg Met Gly Phe Asp Phe Lys Asp Val
 345 350 355

5 aag aaa ata atg gag gaa aga att caa aca tct ggg agc aac tat aaa 1401
 Lys Lys Ile Met Glu Glu Arg Ile Gln Thr Ser Gly Ser Asn Tyr Lys
 360 365 370

10 acg ctt gag gtt ctt gtt gca gat cta gtg agc gct cag aaa gac act 1449
 Thr Leu Glu Val Leu Val Ala Asp Leu Val Ser Ala Gln Lys Asp Thr
 375 380 385

15 aca gaa aat gaa ttg aat cag act tca ttg cag aga gaa atc agc cct 1497
 Thr Glu Asn Glu Leu Asn Gln Thr Ser Leu Gln Arg Glu Ile Ser Pro
 390 395 400

gaa gag ccg cta agg cgt ctg caa gag gag aag ctt tgt aaa atc tgc 1545
 Glu Glu Pro Leu Arg Arg Leu Gln Glu Glu Lys Leu Cys Lys Ile Cys
 405 410 415 420

20 atg gac aga cat atc gct gtt gtt ttt att cct tgt gga cat ctg gtc 1593
 Met Asp Arg His Ile Ala Val Val Phe Ile Pro Cys Gly His Leu Val
 425 430 435

25 act tgt aaa caa tgt gct gaa gca gtt gac aga tgt ccc atg tgc agc 1641
 Thr Cys Lys Gln Cys Ala Glu Ala Val Asp Arg Cys Pro Met Cys Ser
 440 445 450

30 gcg gtt att gat ttc aag caa aga gtt ttt atg tct taa tgtaactcta 1690
 Ala Val Ile Asp Phe Lys Gln Arg Val Phe Met Ser
 455 460 465

cagtgggtgt gctatgttct tattaccctg attaaatgtg tgatgtgact caactttaag 1750

35 tagtcagc 1758

<210> 2
 <211> 464
 <212> PRT
 40 <213> Homo sapiens

<400> 2
 Lys Arg Leu Ile Asp Gln Lys Arg Leu Leu Ala Leu Gln Val Val Gly
 1 5 10 15
 45 Leu Pro Gly His Arg Arg Val Gly Gly Asp Ala Leu Gly Gly Leu Ser
 20 25 30
 Cys Pro Glu Ala Val Asp Arg Trp Gln Arg Gly Gly Ser Gly Val Asp
 35 40 45
 50 Lys His Lys Lys Ala Ala Pro Asn Cys Arg Phe Ile Arg Ser Phe Tyr
 50 55 60
 Phe Glu Asp Ser Ala Thr Lys Pro Ala Asn Pro Gly Val Pro Asn Ser
 65 70 75 80
 Gln Tyr Gln Val Glu Asn His Leu Gly Glu Glu Lys Arg Cys Ala Leu
 85 90 95
 55 Asp Arg Pro Ser Glu Thr Arg Ala Asp Arg Leu Leu Arg Ala Gly Gln
 100 105 110
 Val Val Asp Arg Ser Asp Ser Ile His Pro Arg Ser Pro Ala Met His
 115 120 125
 60 Ser Glu Glu Ala Arg Leu Gln Ser Phe His Asn Trp Pro Ala Ser Ala
 130 135 140
 His Leu Thr Pro Arg Glu Leu Ala Ser Ala Gly Leu Tyr Tyr Thr Gly

	145				150					155				160		
	Thr	Asp	Asp	Gln	Val	Gln	Cys	Phe	Cys	Cys	Gly	Gly	Lys	Leu	Lys	Asn
					165					170					175	
5	Trp	Glu	Pro	Gly	Asp	Arg	Ala	Trp	Ser	Glu	His	Arg	Arg	His	Phe	Pro
				180					185					190		
	Asn	Cys	Phe	Phe	Ile	Leu	Gly	His	Asn	Val	Asn	Ile	Arg	Gly	Glu	Ser
			195					200					205			
	Asp	Val	Ala	Ser	Ser	Asp	Arg	Asn	Phe	Ser	Asn	Ser	Thr	Ser	Ser	Pro
		210					215					220				
10	Arg	Asn	Pro	Ser	Met	Thr	Gly	Tyr	Glu	Ala	Arg	Leu	Ile	Thr	Phe	Gly
		225				230					235					240
	Thr	Trp	Met	Tyr	Ser	Val	Asn	Lys	Glu	Gln	Leu	Ala	Arg	Ala	Gly	Phe
				245					250						255	
	Tyr	Ala	Ile	Gly	Gln	Glu	Asp	Lys	Val	Gln	Cys	Phe	His	Cys	Gly	Gly
15				260					265					270		
	Gly	Leu	Ala	Asn	Trp	Lys	Pro	Lys	Glu	Asp	Pro	Trp	Glu	Gln	His	Ala
			275					280					285			
	Lys	Trp	Tyr	Pro	Gly	Cys	Lys	Tyr	Leu	Leu	Glu	Glu	Lys	Gly	His	Glu
		290					295					300				
20	Tyr	Ile	Asn	Asn	Ile	His	Leu	Thr	Arg	Ser	Leu	Glu	Gly	Ala	Leu	Val
		305				310					315					320
	Gln	Thr	Thr	Lys	Lys	Thr	Pro	Ser	Leu	Thr	Lys	Arg	Ile	Ser	Asp	Thr
				325					330						335	
	Ile	Phe	Pro	Asn	Pro	Met	Leu	Gln	Glu	Ala	Ile	Arg	Met	Gly	Phe	Asp
25				340					345					350		
	Phe	Lys	Asp	Val	Lys	Lys	Ile	Met	Glu	Glu	Arg	Ile	Gln	Thr	Ser	Gly
			355				360						365			
	Ser	Asn	Tyr	Lys	Thr	Leu	Glu	Val	Leu	Val	Ala	Asp	Leu	Val	Ser	Ala
		370					375					380				
30	Gln	Lys	Asp	Thr	Thr	Glu	Asn	Glu	Leu	Asn	Gln	Thr	Ser	Leu	Gln	Arg
						390					395					400
	Glu	Ile	Ser	Pro	Glu	Glu	Pro	Leu	Arg	Arg	Leu	Gln	Glu	Glu	Lys	Leu
				405					410						415	
	Cys	Lys	Ile	Cys	Met	Asp	Arg	His	Ile	Ala	Val	Val	Phe	Ile	Pro	Cys
35				420					425					430		
	Gly	His	Leu	Val	Thr	Cys	Lys	Gln	Cys	Ala	Glu	Ala	Val	Asp	Arg	Cys
			435					440					445			
	Pro	Met	Cys	Ser	Ala	Val	Ile	Asp	Phe	Lys	Gln	Arg	Val	Phe	Met	Ser
		450					455					460				
40																

45 <210> 3
 <211> 1758
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 50 <222> (286)..(687)

<400> 3
 ccttggcggc tccccagagc ggcggtgct aatcgtgggt cgtcagcctg ggtggctggg 60
 55 cccggcttag ggcagggttt ggcatttcca atggtagggg gctcggaccg tccctccgcg 120
 ggaccctccc gttgggacaa ggccgatcgc ctgggcggtt ggagccgcta tcctggcgcg 180
 agacggtgga caagtcctat attcaagaga agataacttt gaacagtttc gaaggatcta 240
 60 aaacgtatgt gtctgcagac atcaatgagg atgaagaatt agtag aag aga tta ata 297

Lys Arg Leu Ile
1

5 gat caa aaa cgt ttg ctg gct ttg cag gtg gtg ggc ctg cct ggg cat 345
 Asp Gln Lys Arg Leu Leu Ala Leu Gln Val Val Gly Leu Pro Gly His
 5 10 15 20

10 cgg cgc gtt gga gga gac gcc ctg ggg ggc ctt agc tgc cct gaa gcg 393
 Arg Arg Val Gly Gly Asp Ala Leu Gly Gly Leu Ser Cys Pro Glu Ala
 25 30 35

15 gta gac agg tgg caa cgt ggg ggc tca gga gtt gac aaa cac aag aaa 441
 Val Asp Arg Trp Gln Arg Gly Gly Ser Gly Val Asp Lys His Lys Lys
 40 45 50

gca gcg ccg aat tgc agg ttt atc cgc agc ttt tat ttt gaa gac agt 489
 Ala Ala Pro Asn Cys Arg Phe Ile Arg Ser Phe Tyr Phe Glu Asp Ser
 55 60 65

20 gcc acg aaa cct gca aat cct ggt gtc cca aat agt caa tac caa gtt 537
 Ala Thr Lys Pro Ala Asn Pro Gly Val Pro Asn Ser Gln Tyr Gln Val
 70 75 80

25 gaa aac cat ctg gga gag gaa aag cgt tgt gct tta gac agg ccg tct 585
 Glu Asn His Leu Gly Glu Glu Lys Arg Cys Ala Leu Asp Arg Pro Ser
 85 90 95 100

30 gag act cgt gca gac cgg ctt ttg aga gct gga cag gtg gtg gat aga 633
 Glu Thr Arg Ala Asp Arg Leu Leu Arg Ala Gly Gln Val Val Asp Arg
 105 110 115

tca gac tcc ata cac ccg agg agc ccc gcc atg cat agt gaa gaa gct 681
 Ser Asp Ser Ile His Pro Arg Ser Pro Ala Met His Ser Glu Glu Ala
 120 125 130

35 aga taa cagtcgtttc acaactggcc agcctctgcc cacttgacct cgagagagct 737
 Arg

40 ggccagtgct gggctgtact acacaggcac tgatgaccaa gtgcagtgct tctgttgtgg 797
 cgaaaaactg aaaaactggg aacctggtga tcgtgcctgg tcagaacaca ggagacattt 857
 tcctaattgc ttctttattt tgggccacaa cgtaaatatt cgaggtgaat ctgatgttgc 917

45 gagttctgat aggaatttct caaattcaac aagttctcca aggaatccat ccatgacggg 977
 ttatgaagcc cggctcatta cttttgggac atggatgtac tccgttaaca aagagcagct 1037
 tgcaagagct ggattttatg ctataggtca agaggataaa gtacagtgct ttcactgtgg 1097

50 aggagggcta gccaactgga agccaagga agatccttgg gaacagcatg ctaaattggta 1157
 tccagggtgc aaatatctgc tagaagagaa gggacatgaa tatataaaca acattcattt 1217

55 aaccggttca cttgaggag ctctgggtaca aactaccaag aaaacacat cactaactaa 1277
 aagaatcagt gataccatct tccctaatcc tatgctacaa gaagctatac gaatgggatt 1337
 tgatttcaag gacgttaaga aaataatgga ggaaagaatt caaacatctg ggagcaacta 1397

60 taaaacgctt gaggttcttg ttgcagatct agtgagcgcct cagaaagaca ctacagaaaa 1457

tgaattgaat cagacttcat tgcagagaga aatcagccct gaagagccgc taaggcgtct 1517
 5 gcaagaggag aagctttgta aaatctgcat ggacagacat atcgctgttg tttttattcc 1577
 ttgtggacat ctggtcactt gtaaacaatg tgctgaagca gttgacagat gtcccatgtg 1637
 cagcgcgggtt attgatttca agcaaagagt ttttatgtct taatgtaact ctacagtggg 1697
 10 tgtgctatgt tcttattacc ctgattaaat gtgtgatgtg actcaacttt aagtagtcag 1757
 c 1758

15 <210> 4
 <211> 133
 <212> PRT
 <213> Homo sapiens

20 <400> 4
 Lys Arg Leu Ile Asp Gln Lys Arg Leu Leu Ala Leu Gln Val Val Gly
 1 5 10 15
 Leu Pro Gly His Arg Arg Val Gly Gly Asp Ala Leu Gly Gly Leu Ser
 20 25 30
 25 Cys Pro Glu Ala Val Asp Arg Trp Gln Arg Gly Gly Ser Gly Val Asp
 35 40 45
 Lys His Lys Lys Ala Ala Pro Asn Cys Arg Phe Ile Arg Ser Phe Tyr
 50 55 60
 30 Phe Glu Asp Ser Ala Thr Lys Pro Ala Asn Pro Gly Val Pro Asn Ser
 65 70 75 80
 Gln Tyr Gln Val Glu Asn His Leu Gly Glu Glu Lys Arg Cys Ala Leu
 85 90 95
 Asp Arg Pro Ser Glu Thr Arg Ala Asp Arg Leu Leu Arg Ala Gly Gln
 100 105 110
 35 Val Val Asp Arg Ser Asp Ser Ile His Pro Arg Ser Pro Ala Met His
 115 120 125
 Ser Glu Glu Ala Arg
 130

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PC/EP 01/08287

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12N15/12 C12N15/63 C12N1/21 C12N15/62 C07K14/47
 C07K16/18 G01N33/53 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C12N C07K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
 EMBL, SEQUENCE SEARCH, EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Dat

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 23568 A (DUCKETT COLIN ;US HEALTH (US); MIR SAMY S (US)) 5 April 2001 (2001-04-05) SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16 the whole document	1-11
X	--- DATABASE EMBL 'Online! accession: AC010467, 17 September 1999 (1999-09-17) DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 19 clone CTD-2287F5, *** SEQUENCING IN PROGRESS ***, 3 ordered pieces." XP002184617 --- -/--	1-8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document but published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
O document referring to an oral disclosure, use, exhibition or other means	*&* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 5 December 2001	Date of mailing of the international search report 20/12/2001
--	--

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Devijver, K
--	---------------------------------------

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08287

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 35693 A (MACKENZIE ALEXANDER E ;BAIRD STEPHEN (CA); UNIV OTTAWA (CA); KORNE) 20 August 1998 (1998-08-20) page 20 -page 29; claims 1-104; figure 1; examples 1-17</p> <p style="text-align: center;">---</p>	1,4,6-8
X	<p>DATABASE WPI Section Ch, Week 200007 Derwent Publications Ltd., London, GB; Class B04, AN 2000-078337 XP002184619 -& JP 11 326328 A (MATSUMOTO K), 26 November 1999 (1999-11-26) SEQ ID NO:3 abstract</p> <p style="text-align: center;">---</p>	1,4,6-8
X	<p>DUCKETT C S ET AL: "A CONSERVED FAMILY OF CELLULAR GENES RELATED TO THE BACULOVIRUS IAP GENE AND ENCODING APOPTOSIS INHIBITORS" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 15, no. 11, 3 June 1996 (1996-06-03), pages 2685-2694, XP000675968 ISSN: 0261-4189 the whole document -& DATABASE EMBL 'Online! accession: U32974; P98170, 11 October 1995 (1995-10-11) DUCKETT C S ET AL: "Human IAP-like protein ILP mRNA, complete cds." XP002184618</p> <p style="text-align: center;">---</p>	1,4,6-8
X	<p>WO 00 05366 A (KORNELUK ROBERT G ;HOLCIK MARTIN (CA); UNIV OTTAWA (CA); LISTON PE) 3 February 2000 (2000-02-03) SEQ ID NO:3; SEQ ID NO:4 page 22 -page 36; claims 1-65; examples 1-8</p> <p style="text-align: center;">---</p>	1,4,6-8
A	<p>DEVERAUX QUINN L ET AL: "IAP family proteins: Suppressors of apoptosis" GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 13, no. 3, 1 February 1999 (1999-02-01), pages 239-252, XP002175394 ISSN: 0890-9369 cited in the application</p> <p style="text-align: center;">-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08287

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
WO 0123568	A	05-04-2001	AU 7621700 A WO 0123568 A2	30-04-2001 05-04-2001
WO 9835693	A	20-08-1998	US 6133437 A AU 7074698 A EP 0991421 A2 WO 9835693 A2 US 6107041 A US 6300492 B1	17-10-2000 08-09-1998 12-04-2000 20-08-1998 22-08-2000 09-10-2001
JP 11326328	A	26-11-1999	NONE	
WO 0005366	A	03-02-2000	US 6159709 A US 6171821 B1 EP 1100900 A2 WO 0005366 A2	12-12-2000 09-01-2001 23-05-2001 03-02-2000